Buprenorphine (Implant)

Introduction Overview

Generic Name

buprenorphine (implant)

Brand Name

Probuphine

Dosage Form

Subdermal implant (rod)

Drug Class

Opioid partial agonist (opioid medication)

Pharmacokinetics

Absorption:
Probuphine delivers buprenorphine continuously at a low but steady dose via subdermal implants placed in the inner upper arm. After implantation, buprenorphine is absorbed directly from the implant into the bloodstream, bypassing the gastrointestinal tract and first-pass hepatic metabolism. The implants maintain a consistent plasma concentration of buprenorphine over approximately 6 months, ensuring stable systemic exposure. This steady-state delivery mitigates peaks and troughs commonly observed with oral or sublingual dosing, thus reducing withdrawal symptoms and cravings. Absorption is influenced by implant placement, local tissue perfusion, and implant integrity.

Distribution:
Buprenorphine exhibits a high affinity for plasma proteins, primarily alpha- and beta-globulins, resulting in approximately 96% plasma protein binding. Upon absorption from the implant, buprenorphine distributes widely to tissues, including the brain due to its lipophilicity, which is critical for its opioid receptor activity. The volume of distribution is estimated to be between 2 to 5 L/kg, indicating extensive tissue binding. Buprenorphine crosses the blood-brain barrier efficiently, exerting its central nervous system effects. Its partial agonist activity at the mu-opioid receptor also influences its distribution kinetics.

Metabolism:
Buprenorphine undergoes extensive hepatic metabolism primarily via cytochrome P450 3A4 (CYP3A4) and UDP-glucuronosyltransferase (UGT) enzymes, converting the drug into norbuprenorphine and glucuronide conjugates. Norbuprenorphine, while active at opioid receptors, has limited central nervous system penetration and contributes less to clinical effect. Metabolic pathways include N-dealkylation and conjugation, with variability influenced by genetic factors, hepatic enzyme inducers, or inhibitors. Because Probuphine delivers buprenorphine steadily, metabolism continues at a consistent rate without large plasma fluctuations.

Elimination:
Buprenorphine and its metabolites are eliminated mainly via biliary excretion into feces and, to a lesser extent, renal excretion. The elimination half-life ranges between 24 to 42 hours in individuals with normal hepatic function, allowing for sustained effects from steady plasma levels provided by the implant. In patients with hepatic impairment, clearance is reduced, prolonging elimination. The implant formulation steadily releases buprenorphine over six months, after which plasma concentrations decline as the drug depot in the implant depletes. Surgical removal of implants halts buprenorphine delivery promptly.

Dosage Forms

Available Dosage Forms:
- Subdermal implant consisting of four 1-inch rods, each containing 74.2 mg buprenorphine
- The implant is inserted subdermally into the inner upper arm using a needle under local anesthesia

Dosages for Adults and Adolescents:
- Single dose consists of 4 implants inserted simultaneously in one upper arm
- Designed to provide continuous buprenorphine delivery for up to 6 months
- Indicated for opioid-tolerant patients aged 16 years and older who have sustained clinical stability on transmucosal buprenorphine (≤8 mg/day or equivalent) for at least 3 months
- After 6 months, implants must be surgically removed; transition back to transmucosal buprenorphine is recommended before considering re-implantation

Specific Patient Populations:
- Approved for adults and adolescents aged ≥16 years with opioid dependence
- Implant insertion and removal must be performed by certified healthcare professionals trained in the procedure
- Not indicated for pain management
- Use in pregnancy requires caution due to risk of neonatal opioid dependence
- Not recommended in patients with hypersensitivity to buprenorphine or with certain local skin or tissue conditions
- Patients with hepatic impairment require careful clinical monitoring

Mechanism Of Action

Buprenorphine, the active agent delivered by Probuphine implants, acts primarily as a partial agonist at the mu-opioid receptor (MOR), a G-protein-coupled receptor implicated in analgesia and opioid dependence. Unlike full opioid agonists such as morphine or methadone, buprenorphine activates these receptors moderately, producing sufficient receptor occupancy to prevent withdrawal symptoms and cravings while limiting maximal opioid effects such as respiratory depression.

At the molecular level, buprenorphine binds with high affinity but low intrinsic activity compared to full agonists, enabling it to functionally block the euphoric effects of other opioids by competitive receptor antagonism. This dual activity provides a ceiling effect for respiratory depression and reduces overdose risk. Additionally, buprenorphine exhibits antagonist activity at kappa-opioid receptors, which may contribute to its antidepressant and anti-craving effects.

Cellularly, buprenorphine’s interaction with MOR inhibits adenylate cyclase activity, reduces cyclic AMP production, and modulates calcium and potassium ion channels, leading to decreased neuronal excitability in pain and reward pathways. This neurochemical modulation stabilizes opioid receptor signaling and attenuates the symptoms of opioid withdrawal.

Clinically, by maintaining stable buprenorphine plasma levels via the Probuphine implant, patients experience continuous receptor engagement, reducing cravings and withdrawal without the peaks and troughs associated with sublingual or other dosing forms. Compared with other long-acting formulations such as Sublocade (monthly injection), Probuphine provides steady, low-dose delivery over six months via a minimally invasive subdermal route. Research, including randomized controlled trials, demonstrates Probuphine’s efficacy in maintaining opioid abstinence and improving treatment adherence in stable patients, reinforcing its role in medication-assisted treatment for opioid use disorder.

Pharmacological Actions

Partial agonist activity at mu-opioid receptors providing opioid effect stabilization
Antagonist activity at kappa-opioid receptors contributing to reduced dysphoria
Competitive binding blocking full opioid agonists and preventing effects of illicit opioid use
Reduction of opioid withdrawal symptoms and cravings through steady receptor occupation
Ceiling effect on respiratory depression enhancing safety relative to full agonists
Modulation of intracellular secondary messenger pathways affecting neuronal excitability
Long-acting continuous release sustaining therapeutic plasma concentrations for up to 6 months
Minimal drug plasma level fluctuations due to subdermal implant delivery
Bypassing first-pass metabolism increases bioavailability compared to oral routes
Reduction in illicit opioid use demonstrated in clinical maintenance therapy trials
Opioid receptor stabilization aiding in psychosocial rehabilitation adherence
Decreased potential for abuse due to partial agonism and route of delivery
Improvement of treatment compliance due to reduced dosing frequency
Lower risk of overdose compared to full opioid agonists
Exertion of central nervous system effects leading to mood stabilization in opioid use disorder

Therapeutic Or Clinical Uses

Maintenance treatment of opioid dependence in patients clinically stable on transmucosal buprenorphine
Medication-assisted treatment (MAT) as part of comprehensive addiction therapy including counseling
Reduction of illicit opioid use and opioid craving in opioid use disorder
Alternatives to daily dosing forms of buprenorphine for improved compliance
Long-term maintenance therapy in opioid-dependent adolescents aged 16 and older
Transition therapy following stabilization on sublingual buprenorphine formulations
Support of opioid abstinence by steady opioid receptor occupancy
Used in opioid-tolerant patients requiring maintenance doses of 8 mg or less daily transmucosal equivalent
Indicated for patients seeking reduced medication administration burden
Non-acute pain treatment is not approved indication; use limited to opioid use disorder
Facilitates reduced risk of diversion and misuse compared to oral formulations
Adjunct to psychosocial interventions to maximize recovery outcomes
Provides steady-state medication delivery in patients with prior treatment stability
Clinical use discontinued in the US but serves as a model for implantable opioid therapies
Use under supervised programs only with certified healthcare providers

Side Or Adverse Effects

Pain, itching, redness, swelling, or bruising at implant insertion site
Implant site bleeding or irritation post-procedure
Headache and depressed mood reported during therapy
Nausea, vomiting, and constipation common opioid-related side effects
Back pain and tooth pain occasionally reported
Sore throat in some patients
Potential serious complications from implant insertion or removal including nerve or blood vessel injury
Risk of opioid withdrawal symptoms such as shivering, sweating, runny nose, diarrhea if drug levels become subtherapeutic
Confusion, agitation, or other alterations in mental status
Extreme drowsiness or cognitive impairment
Respiratory depression or breathing difficulties, including sleep apnea exacerbation
Blurred vision, slurred speech, impaired coordination as neurological side effects
Symptoms of low cortisol including nausea, vomiting, appetite loss, and weakness
Serious allergic reactions including hives, facial swelling, and breathing difficulties
Possible serotonin syndrome when combined with serotonergic drugs

Precautions

Do not use in patients with known allergy to buprenorphine
Assess history of breathing problems, including sleep apnea, before implantation
Caution in patients with liver disease or impaired hepatic function
Evaluate patients for enlarged prostate or urinary retention risk
Screen for Addison’s disease or adrenal insufficiency prior to treatment
Patients with abnormal spinal curvature or neurological disorders require caution
Monitor patients for signs of mental illness or psychosis
Avoid use during pregnancy unless benefits outweigh risks due to neonatal opioid dependence risk
Breastfeeding mothers should consult healthcare provider about risks to infant
Ensure patient understanding of implant insertion/removal risks and safe disposal of implants
Avoid alcohol consumption during treatment due to increased risk of adverse effects
Patients should avoid driving or operating machinery until effects of buprenorphine are known
Avoid combining with other opioid pain medications unless under strict medical supervision
Monitor for signs of infection or implant site complications post-insertion
Educate patients about the need for surgical removal and risks of implant misuse

Warnings

Insertion and removal of Probuphine implants can cause serious or life-threatening complications including nerve and blood vessel damage
Misuse or unauthorized removal of implants can result in addiction, overdose, or fatality especially in children or non-prescribed individuals
Patients with respiratory depression or severe pulmonary disease are at increased risk for opioid adverse effects
Combinations with other central nervous system depressants increase risk of sedation and respiratory failure
Use during pregnancy may cause neonatal opioid withdrawal syndrome requiring prolonged medical treatment
Do not taper dose simply for the purpose of transition to implant therapy; requires clinical stability prior
Risk of serious allergic reactions including anaphylaxis
Avoid abrupt discontinuation to prevent withdrawal symptoms
Patients should be monitored closely for serotonin syndrome when on serotonergic agents concurrently
Keep implants away from children and unauthorized persons
Probuphine is only part of a comprehensive treatment program; failure to receive counseling increases risk of relapse
Removal of implants must be performed by trained healthcare professional
Overdose symptoms like severe drowsiness, pinpoint pupils, and respiratory depression need immediate emergency attention
Not recommended for pain management, only for opioid dependence treatment
Inform all healthcare providers about Probuphine therapy to avoid contraindicated drug administration

Contraindication

Known hypersensitivity or allergy to buprenorphine or implant components
Patients with severe respiratory depression or acute asthma attacks
Post-operative patients or those with conditions compromising respiratory function
Individuals with history of significant skin reactions or infections at implant site
Patients under 16 years of age
Patients not clinically stable on transmucosal buprenorphine at ≤8 mg/day equivalent
Use as sole therapy without psychosocial support
Patients with uncontrolled psychiatric disorders or active suicidal ideation
Patients with impaired coagulation or on anticoagulant therapy that contraindicates implantation
Pregnant women unless benefits outweigh risk to fetus
Concurrent use with other opioids without medical supervision
Known or suspected opioid tolerance insufficient for implant therapy
Patients unable or unwilling to comply with follow-up and implant removal procedures
Patients with localized infections or skin diseases at the insertion site
Patients with history of sensitivity to anesthetic agents used in implantation

Drug Interactions

Concurrent use with other opioid medications may increase risk of respiratory depression and sedation
CNS depressants including benzodiazepines (e.g., diazepam, alprazolam, lorazepam) potentiate sedation and respiratory depression
Medications that affect CYP3A4 enzymes (e.g., certain antibiotics, antifungals, antiretrovirals) can alter buprenorphine metabolism leading to toxicity or reduced efficacy
Drugs that induce CYP3A4 may reduce buprenorphine plasma levels causing withdrawal symptoms
Combination with serotonergic agents (SSRIs, SNRIs, triptans) may increase risk of serotonin syndrome
Alcohol use can potentiate sedative effects and increase overdose risk
Certain antihistamines, muscle relaxants, and antipsychotics may exacerbate CNS depression
Use with seizure medications requires monitoring as pharmacokinetics of buprenorphine may be affected
Heart or blood pressure medications may interact and require dose adjustment
Use of opioids for acute pain during Probuphine therapy may require alternative pain management approaches
Medications for gastrointestinal conditions such as irritable bowel syndrome or overactive bladder may interact
Avoid use with drugs causing respiratory depression unless under strict supervision
Herbal supplements and over-the-counter drugs may interfere with metabolism or enhance side effects
Drug interactions can result in precipitated withdrawal or overdose; full medication list review essential
Not all interactions have been identified; clinical monitoring necessary throughout therapy

Preparations Of The Drug

Probuphine implant: a single dose consists of 4 subdermal rods, each containing 74.2 mg buprenorphine
Implants are sterile, non-biodegradable rods designed for subdermal insertion lasting about 6 months
Packaging includes sterile delivery needle, implant rods, and procedural instructions for certified providers
Local anesthetics are used during insertion and removal to minimize patient discomfort
Implants must be stored according to manufacturer’s guidelines to maintain stability
Not available as oral, injectable, or transdermal formulations under the brand Probuphine
Other buprenorphine formulations include sublingual tablets (Subutex), sublingual film (Suboxone), monthly injections (Sublocade), and transdermal patches (Butrans)
Probuphine brand has been discontinued in the US; no generic implant widely available as of last update
Used as part of structured opioid use disorder programs integrating pharmacotherapy and counseling
Implants must be removed surgically at end of treatment duration or if adverse effect occurs
Distribution restricted to certified pharmacies and healthcare providers in a REMS-like program
Patient education materials and medication guides accompany each preparation
Strict controls prevent implant misuse or diversion
Additional supportive treatments and alternatives (methadone, naltrexone) exist for opioid dependence
Adjunct medical tools include emergency opioid antagonists like naloxone nasal spray for overdose reversal